STOCKS TELEGRAPH

Tag: Quantum BioPharma

  • Quantum BioPharma (QNTM) Stock Rallies Following Key Business Development

    Quantum BioPharma (QNTM) Stock Rallies Following Key Business Development

    As of the most recent check, shares of Quantum BioPharma Ltd. (NASDAQ: QNTM) were up 14.51% to $6.71, a notable increase on the charts. The recent product launch by its licensee, Celly Nutrition Corporation, is responsible for the notable surge in QNTM stock value. This further solidifies the company’s position in the expanding wellness and healthcare sector.

    Unbuzzd Product Line Expansion

    The creator of the novel beverage “unbuzzd,” Celly Nutrition Corporation, unveiled their new “On-the-Go Powder Stick Packs” in an 8-pack display box. This calculated growth makes it easier to sell unbuzzed in pharmacies, liquor shops, and convenience stores across the US.

    Well-positioned in the projected $2.1 billion worldwide hangover treatment industry, unbuzzd is designed to speed up alcohol metabolism, restore mental clarity, and reduce hangover symptoms. It is anticipated that the new package type would give customers instant accessibility while increasing product awareness and store profitability.

    As of June 30, 2024, Quantum BioPharma still owns 25.71% of Celly Nutrition and enjoys the advantages of a well-structured royalty arrangement. Until total payments exceed $250 million, the corporation will earn a 7% royalty on unbuzzed purchases; after that, royalties will be lowered to 3% in perpetuity. To further broaden its commercial portfolio, QNTM also has the exclusive right to create pharmaceutical or medical versions of comparable items.

    Digital Asset Moves

    In addition to its product efforts, Quantum BioPharma has systematically increased its bitcoin holdings. QNTM now has $3.5 million in cryptocurrency assets after investing an extra $1.5 million in Bitcoin and other digital assets.

    This decision reflects the company’s trust in digital assets as a hedge against currency volatility and a possible source of investment returns, and it is consistent with its goal to use cryptocurrencies for financing and transactions. A completely compliant custodian oversees the management of all bitcoin assets, guaranteeing compliance with audit and financial requirements.

    Recent events demonstrate Quantum BioPharma’s diverse growth strategy, which combines creative product introductions, improved market interaction, and calculated financial diversification to increase long-term shareholder value.

  • Pre-Market Boost For Quantum BioPharma (QNTM) As Clinical Results Impress Investors

    Pre-Market Boost For Quantum BioPharma (QNTM) As Clinical Results Impress Investors

    The stock price of Quantum BioPharma Ltd. (NASDAQ: QNTM) had a spectacular increase during the pre-market session, rising 69.46% to $5.39. This dramatic rise comes after a crucial clinical experiment assessing the effectiveness of its dietary supplement, Unbuzzd, in reducing alcohol intoxication and improving alcohol metabolism was successfully concluded.

    Innovative Trial Shows Effectiveness

    The influence of Unbuzzd on blood alcohol concentration (BAC) and associated intoxication symptoms was evaluated in a recently completed double-blind, randomized, placebo-controlled crossover research. The findings demonstrated that Unbuzzd significantly accelerated the reduction of BAC in study participants while simultaneously alleviating symptoms associated with intoxication and hangovers. All observed effects were statistically significant when compared to the placebo group.

    Notably, the benefits of Unbuzzd became apparent within just 30 minutes of consumption. The supplement’s safety profile was confirmed by the fact that it was well tolerated and that no negative effects were noted. Over the course of the four-hour evaluation period, participants’ BAC decrease rates were, on average, more than 40% quicker than those in the control group during the first half hour.

    Cognitive and Physiological Benefits Confirmed

    Beyond reducing BAC, study participants exhibited statistically significant improvements in mental alertness and cognitive performance within 30 minutes of consuming Unbuzzd. Individuals who took the supplement reported increased focus, enhanced reaction times, and fewer cognitive errors compared to those in the placebo group.

    Additionally, Unbuzzd played a critical role in stabilizing physiological responses to alcohol consumption. Participants experienced less fluctuation in heart rate and blood pressure—common effects of intoxication—highlighting the supplement’s potential to mitigate alcohol-related impairments effectively.

    A Promising Solution for Responsible Alcohol Consumption

    Another key finding from the study was the substantial reduction in hangover severity. Participants who consumed Unbuzzd reported a 67% decrease in headache intensity at the four-hour mark and continued relief at the eight-hour mark. Furthermore, reductions in both cognitive and physical impairment were observed, reinforcing the supplement’s potential benefits for individuals who consume alcohol.

    With no reported safety concerns or adverse effects, this clinical study underscores Unbuzzd’s promise as a scientifically backed solution to minimize the adverse effects of alcohol consumption. As consumers seek effective ways to manage intoxication responsibly, Unbuzzd emerges as a significant addition to the landscape of alcohol-related wellness products.

  • Quantum BioPharma (QNTM) Experiences Pre-Market Boost

    Quantum BioPharma (QNTM) Experiences Pre-Market Boost

    Quantum BioPharma Ltd. (NASDAQ: QNTM) has experienced a notable uptick in its stock performance on the US stock charts today. As per the most recent pre-market data, QNTM shares have risen by 6.08%, reaching a trading value of $4.19. This positive momentum is likely attributed to a debt settlement initiative that commenced last month.

    Executive Bonuses and Debt Settlements

    The board of directors of Quantum BioPharma recently approved incentives of $450,000 for CEOs Donal Carroll, Zeeshan Saeed, and Anthony Durkacz. The decision they made has been made accordance with the conditions specified in their individual executive agreements.

    The executives are eligible for yearly incentives under these agreements, contingent upon meeting predetermined performance targets. Executives are eligible for bonuses equal to 70% of their base income for the second year of work and 80% of their base salary for the third year of employment.

    As a result, the incentives for every year of service for each executive are $210,000 and $240,000, respectively. To manage cash flow while adhering to Canadian Securities Exchange (CSE) policies, the Company plans to settle these bonuses through the issuance of Class B Shares, priced at $5.44 per share.

    The shares will be subject to a four-month and one-day hold period in compliance with CSE regulations and applicable securities laws. The Company anticipates finalizing this debt settlement process by the first week of September 2024 and will issue a subsequent press release upon completion.

    Launch of ‘unbuzzd’

    In addition to financial maneuvers, Quantum BioPharma has recently unveiled ‘unbuzzd,’ an innovative product aimed at addressing the aftereffects of alcohol consumption. The Clear Eyed Citrus Powder Sticks, now available on Amazon.com, represent a significant advancement in alcohol recovery solutions.

    Developed by a leading pharmaceutical research and development team, unbuzzd is distinguished by its scientific formulation combining a proprietary mix of vitamins, minerals, and herbs.

    This dual-action formula is designed to accelerate alcohol metabolism, restore mental clarity, and enhance hydration, offering a comprehensive approach to managing alcohol’s aftermath. As a groundbreaking product in its category, unbuzzd is poised to transform conventional methods of alcohol recovery.